Skandinaviska Enskilda Banken AB publ Boosts Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

Skandinaviska Enskilda Banken AB publ increased its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) by 30.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 22,290 shares of the company’s stock after purchasing an additional 5,189 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Vera Therapeutics were worth $938,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. AlphaQuest LLC bought a new stake in shares of Vera Therapeutics in the 4th quarter worth about $34,000. E Fund Management Co. Ltd. grew its position in Vera Therapeutics by 22.3% in the fourth quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company’s stock worth $262,000 after acquiring an additional 1,130 shares in the last quarter. KBC Group NV increased its stake in Vera Therapeutics by 127.2% during the fourth quarter. KBC Group NV now owns 2,477 shares of the company’s stock worth $105,000 after acquiring an additional 1,387 shares during the last quarter. Arizona State Retirement System raised its position in Vera Therapeutics by 22.9% during the fourth quarter. Arizona State Retirement System now owns 12,586 shares of the company’s stock valued at $532,000 after purchasing an additional 2,348 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Vera Therapeutics by 27.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,427 shares of the company’s stock valued at $568,000 after purchasing an additional 2,882 shares during the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Stock Up 0.3 %

Shares of NASDAQ:VERA opened at $28.07 on Tuesday. The business’s 50 day moving average is $32.73 and its 200 day moving average is $39.58. The stock has a market cap of $1.79 billion, a P/E ratio of -10.75 and a beta of 1.17. Vera Therapeutics, Inc. has a 52-week low of $25.99 and a 52-week high of $51.61. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.11. Sell-side analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on VERA shares. Guggenheim increased their price target on Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a report on Thursday, February 27th. JPMorgan Chase & Co. lowered their target price on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating for the company in a report on Tuesday, March 4th. The Goldman Sachs Group initiated coverage on shares of Vera Therapeutics in a research report on Tuesday, January 28th. They issued a “buy” rating and a $58.00 price objective on the stock. Wells Fargo & Company began coverage on Vera Therapeutics in a research report on Thursday, November 21st. They set an “overweight” rating and a $70.00 target price for the company. Finally, Wolfe Research began coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They set an “outperform” rating and a $49.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $64.67.

Insider Activity

In related news, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total transaction of $730,450.00. Following the transaction, the chief executive officer now directly owns 143,603 shares of the company’s stock, valued at $5,993,989.22. This trade represents a 10.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 21.70% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.